Sanj K. Patel - 16 Mar 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role
CHAIRMAN & CEO, Director
Signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
16 Mar 2025
Net transactions value
-$45,310
Form type
4
Filing time
19 Mar 2025, 17:49:35 UTC
Previous filing
08 Nov 2024
Next filing
03 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Options Exercise +6,569 +8.3% 86,120 16 Mar 2025 Direct F1
transaction KNSA Class A Ordinary Share Tax liability $45,310 -2,004 -2.3% $22.61 84,116 16 Mar 2025 Direct
holding KNSA Class A Common Share 109,795 16 Mar 2025 Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Restricted Share Unit Options Exercise $0 -6,569 -100% $0.000000 0 16 Mar 2025 Class A Ordinary Share 6,569 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2 The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.